JP2017503481A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503481A5 JP2017503481A5 JP2016536527A JP2016536527A JP2017503481A5 JP 2017503481 A5 JP2017503481 A5 JP 2017503481A5 JP 2016536527 A JP2016536527 A JP 2016536527A JP 2016536527 A JP2016536527 A JP 2016536527A JP 2017503481 A5 JP2017503481 A5 JP 2017503481A5
- Authority
- JP
- Japan
- Prior art keywords
- dlbcl
- lenalidomide
- patient
- pharmaceutically acceptable
- isomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361913046P | 2013-12-06 | 2013-12-06 | |
| US61/913,046 | 2013-12-06 | ||
| PCT/US2014/068767 WO2015085160A2 (en) | 2013-12-06 | 2014-12-05 | Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunodulatory therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017503481A JP2017503481A (ja) | 2017-02-02 |
| JP2017503481A5 true JP2017503481A5 (https=) | 2018-01-18 |
Family
ID=53274284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536527A Pending JP2017503481A (ja) | 2013-12-06 | 2014-12-05 | 血液癌を治療する方法及び免疫調節療法に対する臨床的感受性の予測因子としてのバイオマーカーの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160312292A1 (https=) |
| EP (1) | EP3077547A4 (https=) |
| JP (1) | JP2017503481A (https=) |
| KR (1) | KR20160090390A (https=) |
| AU (1) | AU2014360316A1 (https=) |
| BR (1) | BR112016012792A2 (https=) |
| CA (1) | CA2932266A1 (https=) |
| EA (1) | EA201691143A1 (https=) |
| IL (1) | IL245936A0 (https=) |
| MX (1) | MX2016007179A (https=) |
| PH (1) | PH12016501023A1 (https=) |
| WO (1) | WO2015085160A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160282354A1 (en) | 2013-11-08 | 2016-09-29 | The Broad Institute, Inc. | Compositions and methods for selecting a treatment for b-cell neoplasias |
| IL278381B2 (en) | 2013-12-06 | 2024-08-01 | Celgene Corp | Methods for determining the effectiveness of a drug for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancer |
| EP3207521B1 (en) * | 2014-10-17 | 2022-11-02 | Stichting Maastricht Radiation Oncology "Maastro Clinic" | Image analysis method supporting illness development prediction for a neoplasm in a human or animal body |
| WO2016196580A1 (en) | 2015-06-02 | 2016-12-08 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins |
| US11459613B2 (en) | 2015-09-11 | 2022-10-04 | The Brigham And Women's Hospital, Inc. | Methods of characterizing resistance to modulators of Cereblon |
| CA2999179A1 (en) * | 2015-09-25 | 2017-03-30 | Celgene Corporation | Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| CA3010801A1 (en) | 2016-01-08 | 2017-07-13 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| JP7357921B2 (ja) * | 2017-09-29 | 2023-10-10 | 国立大学法人九州大学 | びまん性大細胞型ｂ細胞リンパ腫患者における化学療法に対する治療効果を予測するための方法及びキット |
| CA3154890A1 (en) * | 2019-10-21 | 2021-04-29 | Maria Soraya Carrancio ANTON | Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dion |
| WO2024258819A1 (en) * | 2023-06-15 | 2024-12-19 | The Broad Institute, Inc. | Neoplastic cytotoxicity induced by glycosylation |
| FR3158743A1 (fr) * | 2024-01-30 | 2025-08-01 | Universite Grenoble Alpes | Biomarqueurs et outil pronostique pour les patients atteint de lymphomes b diffus a grandes cellules |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2235213A2 (en) * | 2007-12-20 | 2010-10-06 | Celgene Corporation | Use of micro-rna as a biomarker of immunomodulatory drug activity |
| TWI509247B (zh) * | 2010-03-12 | 2015-11-21 | 西建公司 | 利用雷那度胺（ｌｅｎａｌｉｄｏｍｉｄｅ）治療非霍奇金氏淋巴瘤之方法及作為預測子之基因及蛋白質生物標記 |
| CA2834535A1 (en) * | 2011-04-29 | 2012-11-01 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
-
2014
- 2014-12-05 KR KR1020167017539A patent/KR20160090390A/ko not_active Withdrawn
- 2014-12-05 EP EP14867978.0A patent/EP3077547A4/en not_active Withdrawn
- 2014-12-05 EA EA201691143A patent/EA201691143A1/ru unknown
- 2014-12-05 MX MX2016007179A patent/MX2016007179A/es unknown
- 2014-12-05 BR BR112016012792A patent/BR112016012792A2/pt not_active Application Discontinuation
- 2014-12-05 JP JP2016536527A patent/JP2017503481A/ja active Pending
- 2014-12-05 US US15/101,866 patent/US20160312292A1/en not_active Abandoned
- 2014-12-05 CA CA2932266A patent/CA2932266A1/en not_active Abandoned
- 2014-12-05 WO PCT/US2014/068767 patent/WO2015085160A2/en not_active Ceased
- 2014-12-05 AU AU2014360316A patent/AU2014360316A1/en not_active Abandoned
-
2016
- 2016-05-31 IL IL245936A patent/IL245936A0/en unknown
- 2016-05-31 PH PH12016501023A patent/PH12016501023A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017503481A5 (https=) | ||
| JP2016500110A5 (https=) | ||
| RU2015125575A (ru) | Композиции и способы для лечения злокачественной опухоли | |
| Tan et al. | Identification of circulating long non-coding RNA GAS5 as a potential biomarker for non-small cell lung cancer diagnosisnon-small cell lung cancer, long non-coding RNA, plasma, GAS5, biomarker | |
| Wu et al. | Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone | |
| Chan et al. | Personalized therapy for hepatocellular carcinoma: Where are we now? | |
| JP2014144959A5 (https=) | ||
| BR112017025254A2 (pt) | ?métodos para detecção de pelo menos uma mutação em uma pluralidade de genes relacionados ao câncer, selecionar um indivíduo para tratamento e prever a probabilidade de capacidade de resposta ao tratamento? | |
| JP2016537010A5 (https=) | ||
| JP2016536303A5 (https=) | ||
| WO2018007872A9 (en) | Biomarkers for inflammatory bowel disease | |
| JP2016501013A5 (https=) | ||
| JP2015530877A5 (https=) | ||
| WO2015057968A3 (en) | Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same | |
| Kim et al. | OCT-1, ABCB1, and ABCG2 expression in imatinib-resistant chronic myeloid leukemia treated with dasatinib or nilotinib | |
| Chen et al. | CCL22 and IL-37 inhibit the proliferation and epithelial-mesenchymal transition process of NSCLC A549 cells | |
| Chen et al. | Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel | |
| Yu et al. | A meta‐analysis: micro RNA s’ prognostic function in patients with nonsmall cell lung cancer | |
| JP2016510591A5 (https=) | ||
| Wang et al. | Effects of miR-455 on PIK3R1 gene expression regulation and kidney cancer cell functions. | |
| MX2016012718A (es) | Determinación de polimorfismos de un solo nucleótido útil para predecir la respuesta para rasagilina. | |
| JP2015517500A5 (https=) | ||
| WO2023023592A1 (en) | Repurposing drugs for non-small cell lung cancer | |
| An et al. | Lower Ras expression as an independent predictor of patient outcomes in lung cancer treated with bevacizumab plus chemotherapy | |
| Lee et al. | Determining the effect of transforming growth factor-β1 on cdk4 and p27 in gastric cancer and cholangiocarcinoma |